F. Hoffmann-La Roche AG


Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Roche retains sole responsibility for content © 2017 F. Hoffmann-La Roche Ltd. All trademarks used or mentioned in this release are protected by law.

1 January 2016 - 31 December 2016

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for F. Hoffmann-La Roche AG published between 1 January 2016 - 31 December 2016 which are tracked by the Nature Index.

Hover over the donut graph to view the WFC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

84 36.43 36.43

Outputs by subject (WFC)

Subject AC FC WFC
Life Sciences 60 24.58 24.58
Chemistry 28 13.09 13.09
Physical Sciences 1 0.65 0.65

Highlight of the month: F. Hoffmann-La Roche AG

Link found between Alzheimer’s risk genes

© Chris Parsons/Digital Vision/Getty

© Chris Parsons/Digital Vision/Getty

Some genetic mutations lead to earlier onset of Alzheimer’s disease by dismantling the brain’s cleaning machinery, a study published in Neuron reveals.

Genentech scientists investigated a protein called TREM2, of which mutated forms can lower the age of Alzheimer’s onset by three years. TREM2 is found on the surface of immune cells called microglia, which help maintain the brain by engulfing floating waste.

The team isolated microglia from mice and discovered mutated forms of TREM2 that prevented shuttling molecules from docking to the microglia. These shuttling molecules pick up beta-amyloid molecules, which can aggregate to form the toxic amyloid plaques found in the brains of Alzheimer’s patients.

The scientists propose that the mutations in TREM2 prevent microglia from engulfing beta-amyloid, allowing the toxic amyloid plaques to form. They also revealed a link between TREM2 and two other genetic risk factors for Alzheimer’s disease that interfere with the same brain-cleaning process.

  1. Neuron 91,328–340 (2016). doi: 10.1016/j.neuron.2016.06.015

View the article on the Nature Index

1 January 2016 - 31 December 2016

International vs. domestic collaboration by WFC

  • 9.98% Domestic
  • 90.02% International

Note: Hover over the graph to view the percentage of collaboration.

Note: Collaboration is determined by the weighted fractional count (WFC), which is listed in parentheses.

Affiliated joint institutions and consortia

Return to institution outputs